NEOPLASMS

This early-phase study tested the safety of combining multiple cancer drugs (niraparib, TSR-022, bevacizumab, chemotherapy, and TSR-042) in 60 people with advanced or metastatic solid tumors. The goal was to find safe doses for future studies. Participants had different types of …

This early-stage study tested an experimental drug called JNJ-70218902 in 82 people with advanced solid tumors, including prostate cancer that had stopped responding to standard treatments. The drug works by redirecting the body's T cells to attack cancer cells. The main goals we…

This early-phase study tested a new drug called vibostolimab (MK-7684), either alone or combined with pembrolizumab and other chemotherapy drugs, in adults with advanced solid tumors that had no standard treatment options. The main goals were to check safety, find the right dose,…

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see how the drug affects the body. TdCyd aims to reactivate genes that slow tumor growth, potenti…

This early-phase study tested a new drug called LY3039478 in 247 adults with advanced or metastatic cancer (including lymphoma) that had not responded to standard treatments. The main goals were to find a safe dose and see if the drug could shrink tumors. Researchers also looked …

This early-stage study tested a new drug called MK-4464, given alone or with another cancer drug (pembrolizumab), in 64 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, how the body processes it,…

This early-phase trial tested a new drug called BI 754091 in 110 adults with advanced solid tumours that could not be removed by surgery or had spread. The main goal was to find a safe dose and check for side effects. Researchers also looked for signs that the drug might shrink t…

This early-stage study tested a new treatment called RD13-02, a type of CAR-T cell therapy, in 2 patients with blood cancers (like leukemia or lymphoma) that had come back or stopped responding to standard treatments. The main goal was to see if the treatment was safe and to lear…

This early-phase trial tested the safety of combining two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard treatments. Participants received the drugs in 21-day cycle…

This early study tested a device called NaviFUS that uses focused ultrasound waves, combined with the standard drug bevacizumab, in 6 adults whose glioblastoma brain tumor had come back after prior treatment. The goal was to see if the combination was safe and could help control …

This study tested whether advanced PET-MRI scans can find prostate cancers that standard MRI might miss. 62 men who were considering focal therapy or prostate removal took part. The goal was to see if the new imaging could better map cancer locations and severity, helping doctors…

This study tested whether a mobile app helps cancer patients recognize and report treatment side effects to their doctors. 222 adults receiving chemotherapy or radiation therapy used the app to track symptoms. The goal was to improve patient involvement in managing their own care…

This study tested a financial navigation program for 258 cancer patients in rural and non-rural North Carolina. The goal was to see if helping patients manage costs could reduce financial toxicity and improve quality of life. Participants had high financial distress and received …

This study looked at the long-term safety of an oral drug called azacitidine in people with blood cancers. Only 5 people who had already taken the drug in earlier studies took part. The main goal was to track any side effects that happened during the extended treatment.

This study looked at 33 adults who had both cancer and immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, causing low counts. Researchers wanted to see if cancer cells mimic platelets, tricking the immune system. They measured how often ITP impr…